Cyclandelate in the treatment of multi-infarct dementia. Interim findings from a multicentre study in general practice.
An open, multicentre clinical trial conducted in general practice was undertaken to investigate the effects of treatment with cyclandelate 800 mg twice daily in elderly patients with multi-infarct dementia. Interim findings in 303 patients demonstrate significant improvements after 12 weeks' treatment in mean scores of cognitive functions, orientation, verbal communications, social behaviour and interest in others and in the environment as assessed by the Blessed Dementia Scale and Parkside Behavioural Scale. Although a placebo response cannot be excluded because of the uncontrolled design of the study, these findings appear to warrant further investigation in well-designed controlled clinical trials in patients with multi-infarct dementia.
D000368:Aged; D002544:Cerebral Infarction / Q000150:complications*; D003495:Cyclandelate / Q000627:therapeutic use*; D003704:Dementia / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D008333:Mandelic Acids; D003495:Cyclandelate